Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 1.00 |
| ▸ | METAP1 | P53582 | 3/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894949 | 1.00 | ACHE (1.00) | ACHEMETAP1HTR2AHTR2CHTR2B | |
| SCHEMBL316629 | 0.86 | ACHE (0.76) | ACHEMETAP1HTR2AHTR2CHTR2B | |
| SCHEMBL5237018 | 0.83 | ACHE (0.71) | ACHEMETAP1HTR2AHTR2CHTR2B | |
| SCHEMBL5237012 | 0.83 | ACHE (0.71) | ACHEMETAP1HTR2AHTR2CHTR2B | |
| SCHEMBL5237022 | 0.83 | ACHE (0.71) | ACHEMETAP1HTR2AHTR2CHTR2B | |
| SCHEMBL19553953 | 0.82 | ACHE (0.69) | ACHEMETAP1 | |
| SCHEMBL29979915 | 0.82 | ACHE (0.69) | ACHEMETAP1 | |
| SCHEMBL29979580 | 0.82 | ACHE (0.69) | ACHEMETAP1 | |
| SCHEMBL19553678 | 0.82 | ACHE (0.69) | ACHEMETAP1 | |
| SCHEMBL1180262 | 0.81 | ACHE (0.69) | ACHEMETAP1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479813-B2 | Method of therapeutically treating cancer | ADT PHARMACEUTICALS, LLC (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250009924-A1 | Indane Derivatives for Malodor Counteraction | FIRMENICH SA (CH) | 2025-01-09 | — | — | US | disclosed |
| CN-117797295-A | Indane derivatives for malodor counteracting | 弗门尼舍有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | UNIVERSITY OF SOUTH ALABAMA (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| EP-4053105-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT Pharmaceuticals, LLC (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220218860-A1 | INDANE DERIVATIVES FOR MALODOR COUNTERACTION | FIRMENICH SA (CH) | 2022-07-14 | — | — | US | disclosed |
| US-20220106250-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | UNIVERSITY OF SOUTH ALABAMA (US) | 2022-04-07 | — | — | US | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5420289-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS AND CYTOPROTECTIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-05-30 | — | — | US | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| US-5229516-A | Antiinflammatory agents, antiallergens and cytoprotective agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0502106-A1 | SUBSTITUTED INDOLE-, INDENE-, PYRANOINDOLE- AND TETRAHYDROCARBAZOLE- ALKANOIC ACID DERIVATIVES AS INHIBITORS OF PLA2 AND LIPOXYGENASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-09 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1991006537-A2 | SUBSTITUTED INDOLE-, INDENE-, PYRANOINDOLE- AND TETRAHYDROCARBAZOLE- ALKANOIC ACID DERIVATIVES AS INHIBITORS OF PLA2 AND LIPOXYGENASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-05-16 | — | — | WO | disclosed |
| US-4061771-A | Ethynylindenyl compounds and derivatives thereof used in the treatment of pain, fever and inflammation | WILLIAM H. RORER, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-3983253-A | Ethynylindenyl compounds and derivatives thereof used in the treatment of pain, fever and inflammation | WILLIAM H. RORER, INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | ACHE 982/4885METAP1 4480/4885HTR2A 1103/4885 |
| US-20250009924-A1 | Indane Derivatives for Malodor Counteraction | MAL2, MTNR1A, LPO | ACHE 8/4885METAP1 779/4885HTR2A 1110/4885 |
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | PRDX3, PRDX5, SQOR | ACHE 3525/4885METAP1 4126/4885HTR2A 3920/4885 |
| US-12479813-B2 | Method of therapeutically treating cancer | RECQL, RDX, RNASE1 | ACHE 1258/4885METAP1 3949/4885HTR2A 2932/4885 |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | ACHE 982/4885METAP1 4480/4885HTR2A 1103/4885 |
| US-20220218860-A1 | INDANE DERIVATIVES FOR MALODOR COUNTERACTION | MAL2, MTNR1A, LPO | ACHE 8/4885METAP1 779/4885HTR2A 1110/4885 |
| US-20220106250-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | PRDX3, PRDX5, SQOR | ACHE 3525/4885METAP1 4126/4885HTR2A 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.